Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma

This article was originally published in The Pink Sheet Daily

Executive Summary

Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.

You may also be interested in...

Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce

AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.

Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A

With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.

Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011

Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts